Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $231.1 million.

  • Abeona Therapeutics' Liabilities and Shareholders Equity rose 9163.38% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $685.6 million, marking a year-over-year increase of 7427.03%. This contributed to the annual value of $108.9 million for FY2024, which is 7019.94% up from last year.
  • Per Abeona Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $231.1 million for Q3 2025, which was up 9163.38% from $246.2 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $246.2 million for Q2 2025, and its period low was $38.8 million during Q3 2022.
  • For the 5-year period, Abeona Therapeutics' Liabilities and Shareholders Equity averaged around $101.3 million, with its median value being $79.6 million (2021).
  • As far as peak fluctuations go, Abeona Therapeutics' Liabilities and Shareholders Equity plummeted by 6743.29% in 2022, and later skyrocketed by 15023.9% in 2024.
  • Over the past 5 years, Abeona Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $79.6 million in 2021, then dropped by 19.31% to $64.2 million in 2022, then fell by 0.33% to $64.0 million in 2023, then soared by 70.2% to $108.9 million in 2024, then surged by 112.15% to $231.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $231.1 million for Q3 2025, versus $246.2 million for Q2 2025 and $99.4 million for Q1 2025.